Introduction {#s2}
============

IL-15 is a 14--15-kD 4-α helix bundle family cytokine member ([@bib141]; [@bib47]). 25 yr ago, IL-15 was identified by our group and that of Grabstein in culture supernatants from two cell lines (Cv-1/EBNA and HuT-102) that stimulated proliferation of the cytokine-dependent T cell line CTLL-2 in the presence of anti--IL-2 antibodies ([@bib5]; [@bib24]; [@bib55]). Since that discovery, there have been \>6,000 papers and \>170 clinical trials involving IL-15, which are beyond the scope of this review and extensively covered in numerous reviews ([@bib130]; [@bib136], [@bib137], [@bib138], [@bib139], [@bib140]; [@bib142], [@bib143]; [@bib47]; [@bib49]; [@bib79]; [@bib10]; [@bib82]; [@bib102]; [@bib114]; [@bib62]; [@bib129]; [@bib92]; [@bib3]; [@bib104]; [@bib103]; [@bib32]; [@bib113]; [@bib77]). Rather, we present a discussion of compelling topics that focuses on IL-15 in the pathogenesis of autoimmune disorders and select malignancies and analyzes approaches to block disordered IL-15 actions. The second theme presented focuses on immunostimulatory aspects and translation of the dramatic effects of IL-15 on natural killer (NK) and CD8 T cells generation and function in development of rational combination therapies for cancer.

IL-15 mRNA is expressed by many tissues; however, IL-15 protein is largely limited to monocytes, macrophages, and dendritic cells ([@bib6]). Although some regulation of IL-15 protein production occurs with transcription, most control of expression is at translation ([@bib6], [@bib7]). Transcription of IL-15 is stimulated by type I and II interferons, CD40 ligation, and TLR stimuli. IL-15 translation is impeded by multiple 5′-untranslated region AUG sequences, a long signal peptide, and a negative regulatory element in the coding sequence C-terminus ([@bib7]). Tight regulation of IL-15 expression is required because of its potency as an inflammatory cytokine. The heterotrimeric IL-15 receptor is composed of common gamma chain (γc) subunit (CD132) shared with IL-2, IL-4, IL-7, IL-9, and IL-21; β chain (βc) subunit (IL-2R/IL-15R, CD122) shared with the IL-2 receptor; and a private IL-15--specific α subunit IL-15Rα (CD215; [@bib47]; [@bib137]). IL-15 binding to IL-2/IL-15Rβ/γc heterodimer induces JAK1 activation that phosphorylates STAT3 via the β chain and JAK3 that phosphorylates STAT5 (STAT5A, STAT5B) via the γ chain ([Fig. 1](#fig1){ref-type="fig"}; [@bib92]).

![**IL-15 signaling pathways.** IL-15, in one scenario at left, binds to the heterotrimeric receptor in cis ([@bib152]; [@bib92]). At right, IL-15 binds to the high-affinity IL-15Rα subunit expressed on antigen-presenting cells and is presented in trans to IL-2/IL-15Rβγ heterodimers on NK or CD8 T cells ([@bib41]). Activation proceeds via three pathways. The first involves JAK1/3/STAT3/5 activation, with phosphorylated STAT proteins forming dimers trafficking to the nucleus for transcriptional activation. In the second IL-15 pathway, adaptor protein Shc binds to a phosphotyrosine residue on IL-2/IL-15Rβ, resulting in activation of the Shc, Grb2, GAB2, P13K, and AkT signaling pathway ([@bib92]). In the third pathway, IL-15 signaling is associated with activation of Grb2 and SOS to form a Grb2/SOS complex that activates the RAS-RAF MAPK pathway involved in cellular proliferation. Collectively, these signaling pathways induce expression and activation of c-Myc, c-Fos, c-Jun, Bcl-2, Bcl-xL, Mcl-1, NF-κB, and TNFα (modified from [@bib92]).](JEM_20191062_Fig1){#fig1}

IL-15 and IL-2 have several common functions including facilitating development of NK cells that reflect their sharing of receptor components IL-2/IL-15Rβ and γc and their use of common JAK1/3 and STAT3/5 signaling ([@bib26]; [@bib54]; [@bib46]; [@bib137]; [@bib57]). However, NK cell development is fairly normal in the absence of IL-2, whereas IL-15 is required for normal NK development. There are also distinctions between IL-2 and IL-15 in adaptive immune responses. IL-2 acts as a growth factor during initiation of immune responses but also has crucial roles in preventing immunity to self by termination of T cell immune responses by activation-induced cell death (AICD) and by action of regulatory T cells (T reg cells; [@bib75]; [@bib128]; [@bib119]).

In contrast, IL-15 has no major net effect on maintenance of T reg cell fitness. IL-15 provides a sustained immune response to invading pathogens by being an antiapoptotic factor; in particular, in IL-15 transgenic mice, IL-2--induced AICD is inhibited ([@bib86]). In addition, IL-15 promotes maintenance of CD44hi CD8 T cell memory phenotype cells and renewal of viral specific memory CD8 T cells ([@bib9]; [@bib22]; [@bib121]; [@bib98]; [@bib105]; [@bib20]; [@bib23]). Furthermore, IL-15 is critical in development of tissue memory phenotype CD103^+^CD28^−^CD8^+^ T cells ([@bib83]; [@bib87]) and for the maintenance of CD4^+^ T cells, CD8αα (+) intraepithelial lymphocytes ([@bib73]; [@bib68]), and ILC1, 2, and 3 innate lymphoid cells ([@bib112]; [@bib52]), and innate cells that express CD103^+^, CD56^+^, and CD44^+^ ([@bib124]).

IL-2 is a predominantly secreted molecule with wider effects, whereas IL-15 is secreted only in small quantities; membrane-bound IL-15 induces signaling in cell--cell contact at an immunological synapse. IL-15 and IL-15Rα coexpressed by monocytes and dendritic cells become associated on cell surfaces where IL-15 is presented in trans to NK and CD8 memory T cells ([@bib41]; [@bib70]; [@bib81]; [@bib58]; [@bib27]). In addition, [@bib152]) demonstrated that IL-15 cis presentation is required for optimal NK cell activation in LPS-mediated inflammatory conditions.

IL-15 in autoimmune diseases {#s3}
============================

IL-15 is a proinflammatory cytokine that [@bib88] suggested is at the apex of the proinflammatory cytokine cascade preceding expression of TNFα and inflammatory cytokines. In an elegant opinion article, [@bib61] proposed that IL-15 functions as a danger signal to regulate tissue-resident T cells and limit tissue destruction. IL-15 contributes to tissue protection by promoting elimination of infected cells, but chronically dysregulated IL-15 promotes organ-specific autoimmune diseases. IL-15 is constitutively up-regulated in a wide variety of autoimmune diseases: rheumatoid arthritis ([@bib56]; [@bib11]), multiple sclerosis ([@bib132]; [@bib106]), systemic lupus erythematosus ([@bib4]; [@bib110]), alopecia areata ([@bib148]), vitiligo ([@bib107]), psoriasis ([@bib133]; [@bib18]), type 1 diabetes ([@bib30]), and celiac disease ([@bib1]; [@bib71]; [@bib89]). Disordered expression of IL-15 by resident cells is often associated with up-regulated expression of ligands for activating NK receptors including NKG2D. The severity of rheumatoid arthritis was related to IL-15--induced expansion of CD4^+^ CD28^−^ T cells expressing NKG2D and stress-induced MHC class I--related chain ligands on rheumatoid synoviocytes ([@bib8]). An antibody to IL-2Rβ that targets IL-15 and IL-2 was effective in a preclinical model of vitiligo ([@bib107]). Celiac disease is characterized by induction of NKG2D ligands and HLA-E ([@bib149]; [@bib1]; [@bib44]). IL-15 promotes expansion of intestinal intraepithelial lymphocytes, which have cytotoxic activity and kill epithelial cells. Alopecia areata was shown to be driven by cytotoxic CD8 T cells that express NKG2D responding to IL-15 ([@bib148]). Administration of ruxolitinib, a JAK1 and JAK2 inhibitor, to patients with alopecia areata restored near complete hair growth, supporting IL-15's pathogenic role ([@bib84]). To investigate the role of IL-15/IL-15Rα in the pathogenesis of type 1 diabetes, we generated double transgenic mice with pancreatic β cells expressing IL-15 and IL-15Rα ([@bib30]). The mice developed hyperglycemia, mononuclear infiltration, β cell destruction, and anti-insulin autoantibodies mimicking early human type 1 diabetes, and hyperglycemia was reversed by inhibiting IL-15 signaling with anti-IL-2/IL-15Rβ (anti-CD122) or pan JAK inhibitor tofacitinib. We demonstrated data supporting IL-15's role in human type 1 diabetes showing pancreatic β cell expression of IL-15 and IL-15Rα in diabetic individuals but not in control subjects ([@bib30]). Abadie and Jabri ([@bib1]; [@bib61]) propose that two signals are required for tissue destruction in type 1 diabetes and celiac disease. The latent potential for autoimmune diseases like celiac disease and diabetes in adults are characterized by dysregulated immune responses to gluten and β islet cell antigens, respectively, with preservation of functional tissue. IL-15 up-regulation is absent in intestinal epithelium and β islet cells of these patients, which supports the hypothesis that tissue disruption by cytotoxic T cells requires IL-15 signals to license them to kill target cells ([@bib61]).

IL-15 plays a role in diverse T cell malignancies {#s4}
=================================================

IL-15 transgenic mice develop fatal lymphocytic leukemias with CD8 phenotype and with NK surface markers ([@bib48]; [@bib120]). IL-15 treatment up-regulates NK markers in both mice and humans.

Retrovirus HTLV-1 infection results in adult T cell leukemia (ATL), a leukemia of T reg cells in 2--5% of infected individuals ([@bib35]). HTLV-1 associated protein Tax transactivates two autocrine (IL-2/IL-2R and IL-15/IL-15R) and one paracrine (IL-9) pathway, yielding activating JAK1/3 and STAT3/5, resulting in spontaneous leukemic cell proliferation that is inhibitable ex vivo by anti-cytokine antibodies or JAK inhibitors ([@bib28]; [@bib64]), which is being evaluated in a clinical trial by our group (NCT01712659) with the JAK inhibitor ruxolitinib. [@bib40] demonstrated that IL-15 acts as a growth and viability factor in cutaneous T cell lymphoma (CTCL). Mishra and coworkers [@bib91]; [@bib93]) showed that ZEB1 is a transcriptional repressor of IL-15 in T cells and that in CTCL, hypermethylation of the ZEB1 binding region within the IL-15 promoter prevented ZEB1 binding and caused increased IL-15 transcription.

IL-15Rα/IL-15 levels were elevated in T cell large granular lymphocytic (LGL) leukemia ([@bib29]), and a model of survival signaling in T cell LGL leukemia suggested that IL-15 and platelet-derived growth factor are sufficient to reproduce deregulations in T cell LGL leukemia ([@bib153]).

Therapeutic targeting of IL-15, its receptor, or signaling pathway {#s5}
==================================================================

IL-15--inhibiting agents developed include soluble IL-15Rα, mutant IL-15 molecules ([@bib65]; [@bib51]; [@bib158]), anti-IL-15 or IL-2/IL-15Rβ antibodies ([@bib96]; [@bib145]; [@bib126]), and modifications of IL-2 that block IL-15 interaction with its receptor ([@bib94]; [@bib99]), as well as JAK inhibitors ([@bib156]; [Fig. 2](#fig2){ref-type="fig"}).

![**Approaches to block disordered IL-15 actions.** Several agents that inhibit IL-15 activity were developed including soluble IL-15Rα, IL-15 mutein ([@bib65]), antibodies specific for IL-15 or IL-2/IL-15Rβ, mutant modifications of IL-2 (BNZ-1 and 2, H9-RETR), to block IL-15 interaction with its receptors ([@bib94]; [@bib99]), and JAK inhibitors. IL-15 antagonists produced by mutating a glutamine residue to aspartic acid residue at the C-terminus of IL-15 increased survival of pancreatic islet cell allografts. Soluble high-affinity IL-15Rα prevented development of collagen-induced arthritis in mice. An antibody specific for IL-15 was effective in mouse models of autoimmune diseases. We developed humanized antibody (Hu-Mik-Beta-1) specific for IL-2/IL-15Rβ. This antibody blocked trans presentation of IL-15 by antigen-presenting cells to target NK cells and CD8 T cells and prolonged cardiac allograft survival in cynomolgus monkeys ([@bib96]). Clinical studies with Hu-Mik-Beta-1 are underway in patients with refractory celiac disease (NCT01893775) and HTLV-1--associated tropical spastic paraparesis (NCT00076180).](JEM_20191062_Fig2){#fig2}

Engineered modifications of IL-2 that block binding of IL-2 and IL-15 to IL-2/IL-15Rβ and γ chains, simultaneously inhibiting actions of both IL-2 and IL-15 ([@bib94]; [@bib99]; [@bib146]), were generated. The RETR mutant of H9 super IL-2 (denoted H9-RETR) binds to IL-2/IL-15Rβ but not γ chain. BNZ-1, a 24-aa agent analogous to shared elements of the D helix of IL-2 and IL-15, binds to γc and not to IL-2/IL-15Rβ. Both agents prevent IL-2- and IL-15--mediated heterodimerization of IL-2/15R β with γc, which is required for signaling.

IL-15 in the immunotherapy of cancer {#s6}
====================================

Recombinant IL-2 was approved in 1992 by the US Food and Drug Administration ([@bib118]). However, although IL-2 is involved in cancer cell death by immune activation, it also suppresses immune responses by maintenance of CD25^+^Foxp3^+^ T reg cells and participates in AICD ([@bib128]; [@bib119]). Furthermore, IL-2 is associated with multiple serious side effects such as capillary leak syndrome, hypotension, hypoxia, and oliguric renal failure. These issues prompted the search for immunotherapeutics with benefits of IL-2 but fewer negative effects. Whereas IL-15 has immune enhancing properties like IL-2, it does not have major effects on T reg cells but suppresses AICD and has less capillary leak syndrome and vascular complications in mice, nonhuman primates, and patients. Multiple immunotherapy studies in murine models indicated that IL-15 may be valuable in therapy of neoplasia ([@bib21]; [@bib97]; [@bib67]; [@bib134]; [@bib131]). 10-d 20 µg/kg/d administration of IL-15 to rhesus macaques by continuous i.v. infusion (CIV) was associated with 10-fold increases in the number of circulating NK cells and 80--100-fold increases in the number of circulating effector memory CD8 T cells ([@bib127]; [@bib144]).

Clinical trials using IL-15 in the treatment of cancer {#s7}
======================================================

Over 170 clinical trials have been initiated in treatment of cancer using different IL-15 preparations. The results of six of these trials have been published in referenced journals ([Table 1](#tbl1){ref-type="table"}). We initiated a first-in-human phase I trial of recombinant IL-15 administered by i.v. bolus daily for 12 d to adults with metastatic malignancy ([@bib33]). This study started with an initial dose of 3 µg/kg/d. However, after initial patients developed grade 3 hypotension and thrombocytopenia, doses of 1.0 and 0.3 µg/kg/d were added. All nine patients at the 0.3 µg/kg/d dose level received 12 doses without dose-limiting toxicity.

###### IL-15 clinical trials in patients with metastatic malignancy

  IL-15 agent           MTD or expansion dose/dosing schedule                              Study population                                           Serious and notable adverse events                                                                                                                                             Maximum fold increase in total NK cells at MTD   Maximum fold increase in CD56^bright^ NK cells   Maximum fold increase in CD8 T cells   Best clinical response                                                                                            References
  --------------------- ------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------ ------------------------------------------------ -------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------
  *E. coli* rhIL-15     0.3 µg/kg/d bolus i.v. for 12 d consecutively                      18 patients with malignant melanoma or renal cell cancer   Grade 3 hypotension; grade 3 thrombocytopenia; grade 3 ALT and AST elevations                                                                                                  2--3                                             3--4                                             3                                      Stable disease (five patients had 10--30% decrease in marker lesions and two had disappearance of lung lesions)   [@bib33]
  *E. coli* rhIL-15     2 µg/kg/d CIV for 10 d                                             27 patients with metastatic solid tumors                   Two deaths (one due to gastrointestinal ischemia and one due to disease progression); grade 3 bleeding; grade 3 papilledema; grade 3 uveitis; grade 3 hepatic encephalopathy   38                                               358                                              5.8                                    Stable disease                                                                                                    [@bib34]
  *E. coli* rhIL-15     2 µg/kg/d s.c. on days 1--5 and 8--12                              19 patients with advanced solid tumors                     Grade 2 pancreatitis; grade 3 cardiac/chest pain                                                                                                                               10.8                                             39.7                                             3.3                                    Stable disease                                                                                                    [@bib90]
  ALT-803               10 µg/kg i.v. or s.c. weekly for 4 wk                              33 patients with hematological malignancies                Two deaths (one due to sepsis, one due to intracranial hemorrhage); grade 4 sepsis; grade 2 pemphigus                                                                          8                                                8                                                2                                      1 CR, 1 PR, 3 SD                                                                                                  [@bib117]
  ALT-803               20 µg/kg s.c. for 4 wk consecutively every 6 wk                    24 patients (11 i.v., 13 s.c.) with solid tumors           Grade 4 congestive heart failure; grade 4 neutropenia; injection site reaction                                                                                                 3.3                                              6.3                                              1.3                                    No PR or CR                                                                                                       [@bib85]
  ALT-803 + nivolumab   20 µg/kg ALT-803 s.c. combination with i.v. nivolumab every 2 wk   21 patients with metastatic non-small cell lung cancer     Grade 3 myocardial infarction; injection site reaction                                                                                                                         3                                                NA                                               Minor response                         6 PR, 10 SD                                                                                                       [@bib147]

CR, complete response; NA, not available; PR, partial response; SD, stable disease.

Flow cytometry revealed a 10-fold increase in absolute NK cell numbers with the 3 µg/kg/d dose level, as well as significant increases in circulating CD8 T and γδ T cell numbers. The best response was stable disease. Inflammatory cytokines IL-6 and IFNγ were markedly elevated, which coincided with acute clinical toxicities of fever, chills, and blood pressure changes. To reduce toxicity with the goal of reducing maximum serum concentration, excess cytokine release, and macrophage activation syndrome, two additional clinical trials were initiated. One involved subcutaneous recombinant human IL-15 (rhIL-15) given daily five times a week for 2 wk consecutively ([@bib90]). There were two serious adverse events among 19 patients treated: grade 2 pancreatitis, and grade 3 cardiac chest pain, hypotension, and elevated troponin (a dose-limiting toxicity). No objective responses were observed; however, several patients had disease stabilization. The treatment induced expansion of circulating NK cells, especially CD56^bright^ cells ([Fig. 3](#fig3){ref-type="fig"}). There was a proportional but less dramatic increase of CD8^+^ T cells.

![**Comparison of maximum fold increase in number of circulating NK cells with different agents and dosing schedules.** rhIL-15 administered by bolus infusions at the MTD (0.3 μg/kg/d) yielded only a two to threefold increase in NK cells ([@bib33]). rhIL-15 administered s.c. at the expansion dose of 2 μg/kg/d on days 1--5 and 8--12 produced a 10.8-fold increase in total NK cells and a 39.7-fold increase in CD56^bright^ NK cells ([@bib90]). ALT-803 mutant (IL-15/IL-15Rα/IgFc) at 10 μg/kg/wk elicited an eightfold increase in NK cells ([@bib117]). rhIL-15 by CIV at 2 μg/kg/d for 10 d resulted in the greatest increase, with a 38-fold increase in circulating total NK cells and a 358-fold increase in CD56^bright^ NK cells ([@bib34]).](JEM_20191062_Fig3){#fig3}

In a parallel trial, we administered rhIL-15 to patients with metastatic malignancy by CIV for 10 d or in a subsequent trial for 5 d ([@bib34]). We observed two deaths at 4.0 µg/kg/d, one disease progression, and a grade 5 visceral arterial ischemia. An expansion cohort of nine patients was subsequently treated at maximum tolerated dose of 2.0 µg/kg/d. In the CIV trial following maximum serum concentration at 48 h, there was a gradual decline of serum IL-15 concentration to 8% of the maximum level by days 8--10 of the IL-15 infusions. This decline may reflect induction of IL-15 receptor--bearing cells and an increase in the number of IL-2/IL-15Rβ (CD122) receptors per cell that acted as a sink binding rhIL-15. Within 1--3 d of CIV infusion initiation, there was a profound decline in the number of circulating NK and CD8 memory phenotype T cells, followed by a gradual increase until termination of infusions. During 1--3 d following termination of infusions, there was a 38-fold increase in the number of circulating NK cells and a 358-fold increase in the number of circulating CD56^bright^ NK cells ([Fig. 3](#fig3){ref-type="fig"}). Studying purified NK cells in vitro, [@bib50] suggested that continuous treatment with IL-15 exhausts purified NK cells, resulting in decreased viability and a cell cycle arrest gene expression pattern. Furthermore, they proposed that their findings should inform IL-15 dosing strategies. Our studies with IL-15 in vivo by CIV to humans do not support these conclusions ([@bib43]; [@bib34]). The proliferation rate of different subsets of NK cells at termination of 10-d IL-15 CIV assayed by Ki67 was \>90%. The cytolytic capacity of the CD56^bright^ NK subset was very effective. In particular, lytic activity was markedly increased by IL-15 CIV, including antibody-dependent cellular cytotoxicity (ADCC) assessed with CD20 antibody-coated Raji cells, natural cytotoxicity to K562 cells mediated by NKp30 and NKp46, and MICA/NKG2D-mediated cytotoxicity ([@bib43]). These observations on the effects of IL-15 on NK subsets support the view that after 5- or 10-d rhIL-15 CIV, NK cells remain effective and do not support the hypothesis that such strategies would be associated with NK cell exhaustion.

Although rhIL-15 may show efficacy in metastatic malignancy, a particular challenge is that it has a short in vivo survival. Indeed, true IL-15 may not be an IL-15 monomer but may rather be an IL-15Rα/IL-15 heterodimer ([@bib42]; [@bib14]). Therefore, an array of IL-15 agents with IL-15Rα were introduced clinically ([Fig. 4](#fig4){ref-type="fig"}).

![**IL-15 agonists used in immunotherapy**. IL-15 preparations in clinical use include rhIL-15 produced in *Escherichia coli* ([@bib33], [@bib34]), an IL-15N72D mutein with a four to fivefold increase in biological activity ([@bib160]), and heterodimeric mammalian IL-15 ([@bib31]; [@bib13], [@bib14], [@bib15]). Anti-CD20-RLI (Cytune Pharma) is a fusion protein consisting of IL-15 linked to the cytokine-binding (sushi) domain of IL-15Rα ([@bib135]). ALT-803 (Altor Pharmaceutical) represents a mutated (N72D) IL-15 (asparagine replacing aspartic residue) linked to the sushi domain of IL-15Rα that is fused to an IgG-Fc fragment to increase in vivo survival ([@bib78]; [@bib53]; Chen, X., et al. 2015. 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer. Abstr. P347). Not shown, ALT-803 scaffold has been fused to four single chains of the tumor-targeting monoclonal antibody rituximab ([@bib122]). This ALT-803 monoclonal fusion protein prolonged survival in murine models of cancer.](JEM_20191062_Fig4){#fig4}

ALT-803 (IL-15 mutant/IL-15Rα/Ig1fusion protein) was administered i.v. or s.c. to 33 patients with hematological malignancies once weekly for four doses ([@bib117]), and pharmacokinetic analysis revealed prolonged serum concentrations following s.c. compared with i.v. infusion. There were two deaths, one due to sepsis and one due to intracranial hemorrhage deemed to be unrelated to ALT-803. Administrations of ALT-803 or hetIL-15 (mammalian IL-15/IL-15Rα) by s.c. injection were associated with large (30 cm) erythematous plaques, mimicking cellulitis ([@bib117]). The rash was associated with an infiltrate predominantly of CD56+ NKp46^−^ γδ T cells. Development of this complication with both ALT-803 and hetIL-15 precluded further increases in IL-15 doses. As noted in [Fig. 3](#fig3){ref-type="fig"}, rhIL-15 by CIV yielded by far the greatest increases in total NK and CD56^bright^ NK cells.

IL-15 in combination therapy {#s8}
============================

Although diverse forms of IL-15 monotherapy augment the number of NK and CD8 T cells, due to immunological checkpoints, IL-15 will have to be used in combination therapy if it is to become a major factor in the cancer therapy armamentarium ([@bib45]; [@bib115]; [@bib100], [@bib101]; [@bib63]).

Agents to relieve checkpoints on the immune system to optimize IL-15 action {#s9}
===========================================================================

IL-15 is associated with expression of immune checkpoints, including the inhibitory cytokine IL-10, TIM3, and TIGIT, and expression of PD-1 on CD8 T cells ([@bib150], [@bib151]). Furthermore, IL-15 is critical in maintenance of CD122^+^CD8^+^ T reg cells ([@bib109]). The combination of IL-15 superagonist with anti--PD-L1 therapy was more effective than either agent alone in murine tumor models ([@bib72]; [@bib69]; [@bib159]). Furthermore, [@bib39] demonstrated that IL-15 trans-signaling with the receptor-linker-IL-15 (RLI) that consists of human IL-15 covalently linked to the human IL-15Rα sushi domain promotes effector/memory CD8^+^ T cell responses and enhances the antitumor activity of PD-1 antagonists. With ALT-803 in combination with nivolumab in patients with metastatic nonsmall cell lung cancer, 6 of 21 patients manifested an objective response ([@bib147]).

To address checkpoints, we administered IL-15 in combination with antibodies to cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-L1 ([@bib151]). In the CT26 or MC38 colon carcinoma or TRAMP-C2 prostatic cancer syngeneic tumor models, IL-15 alone provided modest antitumor activity. Addition of either anti-CTLA-4 or anti--PD-L1 alone in association with IL-15 did not increase efficacy. However, tumor-bearing mice receiving IL-15 in combination with both anti-checkpoint antibodies manifested a marked prolongation of survival. In translation, a phase I trial is initiated that involves IL-15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers (NCT 03388632).

Combination of IL-15 plus optimized agonistic anti-CD40 {#s10}
=======================================================

As noted above, in rhesus macaques, CIV of IL-15 at 20 µg/kg/d for 10 d led to an 80--100-fold increase in circulating effector memory CD8 T cells. rhIL-15 by CIV to humans led to a lower CD8 T cell response with an up to eightfold increase in the number of circulating activated CD38^+^, MHC Class II^+^ CD8^+^ T cells. However, there was little evidence that the CD8 T cells generated had antitumor activity. IL-15 induces a complex of intracellular regulatory suppressor of cytokine signaling (SOCS) agents ([@bib2]). High concentrations of IL-15 increase expression of CIS encoded by cytokine-inducible SH2-containing protein, a potent checkpoint of NK-mediated tumor immunity ([@bib17]; [@bib38]). Furthermore, SOCS1 attenuates IL-15 receptor signaling of CD8 thymocytes and CD8^+^ CD44^high^ memory T lymphocytes ([@bib59], [@bib60]; [@bib25]). In addition, SOCS2 up-regulation following IL-15 stimulation enhances IL-15--primed human NK cell function via control of phosphorylated Pyk2 ([@bib74]). [@bib125] demonstrated that administration of γc cytokines was often ineffective in cancer immunotherapy because it led to paralysis/depression of CD4 but not CD8 T cells that was mediated through transient expression of SOCS3, which inhibited the STAT5B signaling pathway ([@bib2]; [@bib125]). This paralysis of primary CD4 T cell helper activity prevented generation of tumor-specific CD8 T cells. The role of CD4 helper cell interaction with dendritic cells and CD8 T cells was shown to be alternatively mediated by CD40 agonists ([@bib12]; [@bib108]; [@bib123]). In our studies in the murine syngeneic tumor model, TRAMP-C2 treatment with either IL-15 or agonistic anti-CD40 antibody alone prolonged survival ([@bib154], [@bib155]). However, combination of IL-15 with agonistic anti-CD40 produced markedly additive effects when compared with either agent alone. IL-15 or anti-CD40 alone did not augment the number of tumor-specific CD8 T cells, whereas administration of a combination of IL-15 with anti-CD40 antibody yielded a 10-fold increase in the number of TRAMP-C2 tumor-specific Spas-/SCNC 9H tetramer-positive CD8 T cells. A clinical trial is being initiated using an optimized intralesional anti-CD40 FcγRII-binding antibody in combination with CIV rhIL-15 ([@bib76]; [@bib37]).

IL-15 in combination with anticancer monoclonal antibodies {#s11}
==========================================================

rhIL-15 administration leads to increases in the number of activated NK cells. However, such increases alone were not sufficient to produce antitumor efficacy, likely because most tumors express self-MHC class I molecules that inhibit NK effector functions. Nevertheless, ex vivo cytokine (IL-12, -15, and -18)-induced memory-like natural killer cells exhibited clinical responses in five of nine evaluable patients with acute myeloid leukemia including four complete remissions ([@bib110]; [@bib16]; [@bib116]). Furthermore, [@bib36] demonstrated that patients with metastatic cutaneous melanoma have improved survival rates if their tumor shows evidence of NK cell infiltration. Furthermore, these survival effects were enhanced in tumors that show higher expression of genes that encode NK stimuli such as the cytokine IL-15. Their results provide evidence that NK cells play a role in the regulation of human tumors and highlight potential survival effects associated with increased NK cell activity.

IL-15 preparations have been reported to be of value in combination with in vivo administered monoclonal antibodies ([@bib95]; [@bib147]; [@bib157]; Chen, X., et al. 2015. 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer. Abstr. P347). In particular, an engineered fusion protein linking a soluble form of human IL-15Rα sushi with an antibody demonstrated antitumor responses ([@bib78]). Furthermore, there was enhancement of ADCC and anti-breast cancer efficacy of cetuximab by a chimeric protein encompassing human interleukin-15 ([@bib111]; [@bib100], [@bib101]). In addition, IL-15 enhanced rituximab ADCC against chronic lymphocytic leukemia cells ([@bib95]).

We investigated combination therapy of IL-15 with rituximab in a syngeneic mouse model of EL-4 lymphoma transfected with human CD20 and with alemtuzumab (CAMPATH-1H) in a xenograft model of human ATL ([@bib157]). IL-15 enhanced therapeutic efficacy of both antibodies. Both NK cells and macrophages were critical elements in the chain of interacting effectors involved in augmented ADCC and optimal therapeutic responses. These results provided the scientific basis for a phase I trial of IL-15 combined with alemtuzumab (anti-CD52) for patients with ATL (NCT02689453). Additional trials were initiated with chronic lymphocytic leukemia with rhIL-15 in combination with obinutuzumab (anti-CD20; NCT03759184) and avelumab (anti-PD-L1; NCT03905135).

Ethics
======

All studies were performed under the conditions of the University of Helsinki. All patients signed a written informed consent for participation in clinical studies. Clinical studies were approved by the Intramural Review Board of the National Cancer Institute. Animal studies were approved by the National Cancer Institute Animal Care and Use Committee.

Conclusions and future perspectives {#s12}
===================================

Specific disorders of IL-15 play pathogenic roles in diverse organ-specific autoimmune disorders. With the alternative goal, IL-15 administration to patients with malignancy dramatically increased circulating NK cells and increased CD8 T cell numbers. However, with the exception of JAK inhibitors, none of the IL-15--related study agents directed toward autoimmunity or cancer has received US Food and Drug Administration approval. Therefore, it will be critical to translate outstanding opportunities suggested in animal models into clinical trials. In particular, many strategies to block IL-15 action for autoimmunity that were effective in models or with ex vivo spontaneously proliferating cytokine autocrine cells gave disappointing results in clinical trials. When evaluating efficacy in inhibiting IL-15 action in in vivo approaches, a valuable biomarker of sustained inhibition of IL-15 signaling is a dramatic reduction in the number of circulating NK cells. It is critical for an effective antibody to IL-15 that it inhibit IL-15 administered in vivo as well as in vitro. Two of three antibodies to IL-2 studied by [@bib19] that functioned as inhibitors in vitro were superagonists in vivo. We propose that lack of a marked reduction of NK cells and relative failure of an antibody to IL-15 in treatment of celiac disease may reflect that this antibody was not effective at inhibiting IL-15 in vivo.

In addition, the use of ruxolitinib to interrupt IL-15 signaling through inhibition of JAK1 and JAK2 in patients with cytokine-dependent ATL was not optimal. Due to the action of HTLV-1--associated Tax transactivation of autocrine and paracrine cytokine pathways in leukemic ATL cells, such cells proliferate ex vivo in 6-d cultures. This proliferation was inhibited when ruxolitinib with JAK1 and off-target JAK2 inhibition was added to these cultures. However, ruxolitinib gave disappointing results both in maintaining inhibition of STAT5 phosphorylation and in clinical response when administered to ATL patients. Pharmacokinetic and pharmacodynamic factors contributed to this result in that when administered orally, ruxolitinib inhibited phosphorylation of STAT5 of peripheral blood mononuclear cells only at the 1-h time point and modestly at 3 h but were relatively ineffective in the remaining hours of the day. To address this issue and the off-target JAK2 inhibition of ruxolitinib, present studies are focusing on specific JAK3 and JAK1 inhibitors.

Alternative inhibitors of IL-15 receptor binding include PEGylated BNZ-1, which blocks IL-2 and IL-15 binding when administered to controls, had a survival *t*~1/2~ of ∼5 d, and led to a 70--80% decline in the number of circulating NK cells and an 80--93% decline in T reg cells. This agent is under clinical trial in patients with T cell LGL and with CTCL ([@bib99]; [@bib146]). A second trial of BNZ-2 that blocks IL-15 and IL-21 is being initiated in treatment of patients with refractory celiac disease. Nevertheless, even in this case, it is likely that inhibition of IL-15 receptor binding or signaling pathway alone will not be optimal and that combinations will be of value. To identify combinations, we employed a high-throughput assay to define agent combinations that are additive, including the Bcl-2/Bcl-xL inhibitor navitoclax ([@bib156]). The combination of ruxolitinib with navitoclax demonstrated synergy in murine models of ATL. In addition, the combination manifested activation of caspase 3 and 7 and conversion of Mcl-1 from its 40-kD anti-apoptotic form to a 24-kD pro-apoptotic form. In the future, such combinations of effective IL-15 action inhibitors may be of value in treatment of autoimmune diseases and select T cell malignancies.

With the alternative goal of treating patients with cancer and developing more effective vaccines, novel approaches with IL-15 are being developed to yield desired pharmacokinetics with one dosing per week provided by IL-15/IL-15Rα combinations along with maximal increases in NK and CD8 T cells provided by CIV rhIL-15. ARMO BioSciences is developing a PEGylated IL-15 to prolong survival. Furthermore, Tan and Waldmann are exploring a long-acting rhIL-15 depot for enhanced cancer immunotherapy in which IL-15 is mixed with an aqueous solution of polylactic-co-glycolic acid--PEG, a copolymer that is in solution at room temperature but transitions into a hydrogel at body temperature ([@bib66]). In murine models, rhIL-15 hydrogel yielded immunotherapeutic IL-15 concentrations that persisted for days.

Despite their augmentation of NK cells and CD8 T cells, all IL-15 preparations administered as monotherapy of solid tumors were ineffective due to action of immunological checkpoints that prevented immune responses to self. In particular, there was inhibition of NK cell action by interactions of KIRS and NKG2A with self-class I MHC. There was parallel inhibition of CD8 T cells stimulated by IL-15 due to induction of SOCS3 in CD4 helper T cells, thereby yielding "helpless" CD8 T cells. To circumvent those latter checkpoints, combination trials of IL-15 and multiple other agents are being initiated. These combinations include IL-15 with checkpoint inhibitors, with anti-CD40 to yield tumor-specific CD8 T cells, and with cancer-directed monoclonal antibodies to increase their ADCC and anticancer efficacy.

In summary, our expanding understanding of the role of IL-15 in the life and death of lymphoid cells in health and disease is providing new perspectives for treatment of autoimmune disorders and malignancies.
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